Contrasting of Loxo Oncology Inc. (LOXO) and Pluristem Therapeutics Inc. (NASDAQ:PSTI)

We will be contrasting the differences between Loxo Oncology Inc. (NASDAQ:LOXO) and Pluristem Therapeutics Inc. (NASDAQ:PSTI) as far as dividends, analyst recommendations, profitability, risk, earnings and valuation, institutional ownership are concerned. The two businesses are rivals in the Biotechnology industry.

Valuation & Earnings

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Loxo Oncology Inc. 144.80M 49.86 62.98M -2.08 0.00
Pluristem Therapeutics Inc. N/A 2207.30 27.98M -0.25 0.00

Table 1 showcases the gross revenue, earnings per share and valuation of Loxo Oncology Inc. and Pluristem Therapeutics Inc.

Profitability

Table 2 provides us Loxo Oncology Inc. and Pluristem Therapeutics Inc.’s return on equity, net margins and return on assets.

Net Margins Return on Equity Return on Assets
Loxo Oncology Inc. -43.49% -16.4% -8.7%
Pluristem Therapeutics Inc. 0.00% -91.6% -69.9%

Volatility and Risk

Loxo Oncology Inc. has a beta of 2.22 and its 122.00% more volatile than S&P 500. Competitively, Pluristem Therapeutics Inc.’s beta is 0.46 which is 54.00% less volatile than S&P 500.

Liquidity

Loxo Oncology Inc.’s Current Ratio and Quick Ratio are 3.6 and 3.6 respectively. The Current Ratio and Quick Ratio of its competitor Pluristem Therapeutics Inc. are 3.3 and 3.3 respectively. Loxo Oncology Inc. therefore has a better chance of paying off short and long-term obligations compared to Pluristem Therapeutics Inc.

Analyst Ratings

The following table shown below contains the ratings and recommendations for Loxo Oncology Inc. and Pluristem Therapeutics Inc.

Sell Ratings Hold Ratings Buy Ratings Rating Score
Loxo Oncology Inc. 0 1 5 2.83
Pluristem Therapeutics Inc. 0 0 0 0.00

The average target price of Loxo Oncology Inc. is $207.67, with potential downside of -11.53%.

Insider and Institutional Ownership

Loxo Oncology Inc. and Pluristem Therapeutics Inc. has shares owned by institutional investors as follows: 99.2% and 5.1%. Insiders owned roughly 7.3% of Loxo Oncology Inc.’s shares. Comparatively, Pluristem Therapeutics Inc. has 7.37% of it’s share owned by insiders.

Performance

Here are the Weekly, Monthly, Quarterly, Half Yearly, Yearly and YTD Performance of both pretenders.

Performance (W) Performance (M) Performance (Q) Performance (HY) Performance (Y) Performance (YTD)
Loxo Oncology Inc. -3.59% -23.23% -18.07% -24.66% 70.01% 60.82%
Pluristem Therapeutics Inc. -8.61% -16.36% -26.34% -29.5% -33.76% -28.48%

For the past year Loxo Oncology Inc. had bullish trend while Pluristem Therapeutics Inc. had bearish trend.

Summary

On 6 of the 10 factors Loxo Oncology Inc. beats Pluristem Therapeutics Inc.

Loxo Oncology, Inc., a biopharmaceutical company, develops and sells medicines for patients with genetically defined cancers in the United States. Its lead product candidate comprises larotrectinib, an oral selective inhibitor of tropomyosin receptor kinase (TRK), which is in adult Phase 1 trial, a pediatric Phase 1/2 trial, and an adult/adolescent Phase 2 trial for the treatment of patients with tumor types, such as lung, head and neck, melanoma, colorectal, sarcoma, and breast cancer. The companyÂ’s preclinical programs include LOXO-195, a drug candidate in preclinical development to address predicted acquired resistance mechanisms; RET inhibitor that optimizes potency for rearranged during transfection (RET) fusion proteins, mutations, and anticipated mechanisms of acquired resistance; and FGFR inhibitor that enables potently inhibiting FGFR isoforms comprising four isoforms with tyrosine kinase domains. It has a drug discovery collaboration agreement with Array BioPharma, Inc. to obtain various rights to TRK inhibitor program and oncology targets. Loxo Oncology, Inc. was founded in 2013 and is headquartered in Stamford, Connecticut.

Pluristem Therapeutics Inc., together with its subsidiary, Pluristem Ltd., operates as a bio-therapeutics company in Israel. It focuses on the research, development, clinical trial, and manufacture of cell therapeutic products and related technologies for the treatment of various ischemic, inflammatory, and hematologic conditions, as well as autoimmune disorders. The company develops PLacental eXpanded (PLX) cell therapy products, including PLX-PAD cells, which is Phase III clinical trial for the treatment of critical limb ischemia (CLI) in patients ineligible for revascularization, recovery after surgery for femoral neck fracture, and acute radiation syndrome (ARS), as well as peripheral and cardiovascular, and orthopedic diseases. It also develops PLX-R18 cells that is in Phase I clinical trial for incomplete hematopoietic recovery following hematopoietic cell transplantation, as well as conducts various in-vivo studies for the evaluation of PLX-R18 for the treatment of ARS. The company has collaborative research agreement with the Berlin-Brandenburg Center for Regenerative Therapies; and a license and commercialization agreement for conducting clinical trials and commercialization of its PLX-PAD product in South Korea related to the treatment CLI and intermediate claudication. Pluristem Therapeutics Inc. was founded in 2001 and is based in Haifa, Israel.